Vaxigrip Tetra 15 MCG/0.5 ML, 15 MCG/0.5 ML, 15 MCG/0.5 ML, 15 MCG Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

vaxigrip tetra 15 mcg/0.5 ml, 15 mcg/0.5 ml, 15 mcg/0.5 ml, 15 mcg

مستودع خوري - khoury drug store - a/california/7/2009 (h1n1) pd 09-derived strain 15 mcg/0.5 ml, a/texas/50/2012 (h3n2) derived strain 15 mcg/0.5 ml, b/massachusetts/2/2012 15 mcg/0.5 ml, b/brisbane/60/2008 15 mcg - 15 mcg/0.5 ml, 15 mcg/0.5 ml, 15 mcg/0.5 ml, 15 mcg

Panvax H1N1 vaccine New Zealand - English - Medsafe (Medicines Safety Authority)

panvax h1n1 vaccine

seqirus (nz) ltd - influenza virus a/california/7/2009 (h1n1) - like strain 15ug - suspension for injection - 15 mcg/0.5ml - active: influenza virus a/california/7/2009 (h1n1) - like strain 15ug excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate dihydrate potassium chloride sodium chloride thiomersal water for injection - for active immunisation to prevent influenza disease caused by the influenza a(h1n1) virus, in adults, adolescents and children 10 years of age and older.

Celvapan New Zealand - English - Medsafe (Medicines Safety Authority)

celvapan

baxter healthcare ltd - influenza virus type a haemagglutinin 7.5ug equivalent to a/california/07/2009 (h1n1);   - suspension for injection - 7.5 mcg - active: influenza virus type a haemagglutinin 7.5ug equivalent to a/california/07/2009 (h1n1)   excipient: polysorbate 80 sodium chloride trometamol water for injection - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE- influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) United States - English - NLM (National Library of Medicine)

influenza a (h1n1) 2009 monovalent vaccine- influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated)

sanofi pasteur inc. - influenza a virus a/california/7/2009(h1n1)-like antigen (formaldehyde inactivated) (unii: 5i5hvc73i8) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) - unii:euj84un96z) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons 6 months of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. do not administer influenza a (h1n1) 2009 monovalent vaccine to anyone with a known severe hypersensitivity to egg proteins or any component of the vaccine or life-threatening reactions after previous administration of any influenza vaccine. [see warnings and precautions (5) and description (11) ] sanofi pasteur's influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluzone vaccine) are manufactured by the same process. available information for fluzone vaccine is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluzone vaccine. it is also not known whether these vaccines can cause fetal harm when administered to a pregnant woman or can affect reproduction

AGRIPPAL S1 INFLUENZA VACCINE Singapore - English - HSA (Health Sciences Authority)

agrippal s1 influenza vaccine

seqirus pte. ltd. - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain; influenza virus (sh) b/brisbane/60/2008 - like strain - injection - 15 mcg ha/0.5ml - influenza virus (sh) a/california/07/2009 (h1n1) pdm09- like strain 15 mcg ha/0.5ml; influenza virus (sh) a/hong kong/4801/2014 (h3n2) - like strain 15 mcg ha/0.5ml; influenza virus (sh) b/brisbane/60/2008 - like strain 15 mcg ha/0.5ml

INFLUENZA A (H1N1) 2009 PANDEMIC MONOVALENT VACCINE (WITHOUT ADJUVANT) SUSPENSION Canada - English - Health Canada

influenza a (h1n1) 2009 pandemic monovalent vaccine (without adjuvant) suspension

id biomedical corporation of quebec - haemagglutinin from a/california/7/2009 (h1n1)v-like strain (x-179a) - suspension - 15mcg - haemagglutinin from a/california/7/2009 (h1n1)v-like strain (x-179a) 15mcg - vaccines

INFLUENZA A- H1N1 2009 MONOVALENT VACCINE injection, suspension United States - English - NLM (National Library of Medicine)

influenza a- h1n1 2009 monovalent vaccine injection, suspension

novartis vaccines and diagnostics ltd - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) (unii: k9p8pva2ug) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) - unii:k9p8pva2ug) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for immunization of persons 4 years of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. influenza a (h1n1) 2009 monovalent vaccine should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), or to any component of influenza a (h1n1) 2009 monovalent vaccine, or who has had a life-threatening reaction to previous influenza vaccinations [see description (11)]. novartis’ influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluvirin) are manufactured by the same process. available information for fluvirin is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluvirin. it is also not known whether influenza a (h1n1) 2009 monovalent vaccine or fluvirin can cause fetal harm when administered to

Fluarix New Zealand - English - Medsafe (Medicines Safety Authority)

fluarix

glaxosmithkline nz limited - influenza virus a/california/7/2009 (h1n1) - like strain 30 µg/ml (a/christchurch/16/2010 (nib-74xp) (15 µg ha)); influenza virus a/hong kong/4801/2014 (h3n2) - like strain 30 µg/ml (a/hong kong/4801/2014, nymc x-263b (15 µg ha)); influenza virus b/brisbane/60/2008 - like strain 30 µg/ml (b/brisbane/60/2008 (15 µg ha)) - suspension for injection - active: influenza virus a/california/7/2009 (h1n1) - like strain 30 µg/ml (a/christchurch/16/2010 (nib-74xp) (15 µg ha)) influenza virus a/hong kong/4801/2014 (h3n2) - like strain 30 µg/ml (a/hong kong/4801/2014, nymc x-263b (15 µg ha)) influenza virus b/brisbane/60/2008 - like strain 30 µg/ml (b/brisbane/60/2008 (15 µg ha)) excipient: commercial light duty detergent d-alpha-tocopheryl acid succinate dibasic sodium phosphate dodecahydrate formaldehyde gentamicin sulfate magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride sodium deoxycholate sucrose water for injection - fluarix is indicated for prophylaxis against influenza in adults and children older than six months of age.

FLUAD INFLUENZA VACCINE Singapore - English - HSA (Health Sciences Authority)

fluad influenza vaccine

novartis (singapore) pte ltd - influenza virus (nh) a/california/07/2009 (h1n1) - like strain - injection - >=15 mcg haemagglutinin/0.5 ml

Influvac (season 2015/2016) Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

influvac (season 2015/2016)

abbott biologicals b.v. veerweg 12 - influenza vaccine inactivated (surface antigen): a/california/7/2009/h1n1/pdm09 - like strain a/california/7/2009/nymc x-181, a/switzerland/9715293/2013/h3n2 - like strain a/switzerland/9715293/2013, nib-88, b/phuket/3073/2013 - suspension for i/m and s/c injection - 15mcg haemagglutinin/dose+15mcg haemagglutinin/dose+15mcg haemagglutinin/dose